New Pharmacological Approaches to the Management of Premenstrual Dysphoric Disorder
CNS Drugs · 2023-05 · 37 (5) · 371-379
DOI: 10.1007/s40263-023-01004-9 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift CNS Drugs, online erschienen am 12.05.2023. Verfasst von Inger Sundström-Poromaa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Premenstrual Dysphoric Disorder, Premenstrual Syndrome. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Uppsala University.
Abstract (Originalsprache)
Premenstrual symptoms are experienced by many female individuals during their fertile age. Premenstrual dysphoric disorder (PMDD), a sex-specific mood disorder, affects about 5% of female individuals during the luteal phase of the menstrual cycle. Treatment with selective serotonin reuptake inhibitors represents a valid solution to manage PMDD for many, but not all, patients. Owing to maladaptive neural reactivity to gonadal hormone fluctuations, that is, the putative mechanism postulated to underlie PMDD, drugs suppressing or stabilizing such variations have been tested. Recently, a clinically significant reduction in the severity of the mental symptoms of PMDD was observed upon treatment with a selective progesterone receptor modulator (SPRM), as demonstrated when comparing ulipristal acetate with placebo in a randomised controlled trial. Stable and low progesterone levels, with maintained low-medium oestradiol levels, define the endocrine profile of this treatment. Importantly, the efficacy of SPRM treatment was accompanied by negligible side effects. These promising results represent a headway to understanding the mechanisms behind PMDD symptomatology and opening up new solutions in the management of PMDD. They also call for studies on the long-term efficacy, safety, and viability of SPRMs in female individuals during their fertile age to further support the development of targeted management of female's mental ill-health in relation to the menstrual cycle. The present overview thus seeks to inform about current and new pharmacological approaches to the management of premenstrual dysphoric disorder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
- Department of Women's and Children's Health, Science for Life Laboratory, Uppsala University BMC, POB 593, 75124, Uppsala, Sweden. erika.comasco@neuro.uu.se.
ORCID-Profile: Inger Sundström-Poromaa, Erika Comasco
Förderung
- Uppsala University
Zitieren
APA
Sundström-Poromaa, I., & Comasco, E. (2023). New Pharmacological Approaches to the Management of Premenstrual Dysphoric Disorder. CNS Drugs, 37(5), 371-379. https://doi.org/10.1007/s40263-023-01004-9
Vancouver
Sundström-Poromaa I, Comasco E. New Pharmacological Approaches to the Management of Premenstrual Dysphoric Disorder. CNS Drugs. 2023;37(5):371-379. doi:10.1007/s40263-023-01004-9
BibTeX
@article{SundstrmPoromaa2023,
author = {Sundström-Poromaa, Inger and Comasco, Erika},
title = {New Pharmacological Approaches to the Management of Premenstrual Dysphoric Disorder},
journal = {CNS Drugs},
year = {2023},
volume = {37},
number = {5},
pages = {371--379},
doi = {10.1007/s40263-023-01004-9}
}
EUVIMED